Role of AP-1 in the Coordinate Induction of Rat Glutamate-cysteine Ligase and Glutathione Synthetase by tert -Butylhydroquinone by Yang, Heping et al.
Role of AP-1 in the Coordinate Induction of Rat Glutamate-cysteine
Ligase and Glutathione Synthetase by tert-Butylhydroquinone*
Received for publication, April 19, 2002, and in revised form, June 27, 2002
Published, JBC Papers in Press, July 1, 2002, DOI 10.1074/jbc.M203812200
Heping Yang‡, Ying Zeng‡, Taunia D. Lee‡§, Yang Yang‡, Xiaopeng Ou‡, Lixin Chen‡,
Masudul Haque‡, Richard Rippe¶, and Shelly C. Lu‡
From the ‡Division of Gastroenterology and Liver Diseases, University of Southern California Liver Disease
Research Center, USC-UCLA Research Center for Alcoholic Liver and Pancreatic Diseases, Keck School of Medicine,
University of Southern California, Los Angeles, California 90033 and the ¶Department of Medicine,
University of North Carolina, Chapel Hill, North Carolina 27599
GSH synthesis occurs via two enzymatic steps cata-
lyzed by glutamate-cysteine ligase (GCL, made up of two
subunits) and GSH synthetase (GS). Recently, we de-
scribed coordinate induction of GCL subunits and GS.
To study GS transcriptional regulation, we have cloned
and characterized a 2.2-kb 5-flanking region of the rat
GS (GenBankTM accession number AF333982). One tran-
scriptional start site is located at 51 nucleotides up-
stream of the translational start site. The rat GS pro-
moter drove efficiently luciferase expression in H4IIE
cells. Sequential deletion analysis revealed DNA regions
that are involved in positive and negative regulation.
One repressor identified was NF1. tert-Butylhydroqui-
none (TBH) exerted a dose- and time-dependent in-
crease in the mRNA level and promoter activity of both
GCL subunits and GS. TBH increased protein binding to
several regions of the GS promoter, c-jun expression,
and activator protein 1 (AP-1) binding activity to several
of the putative AP-1-binding sites of the GS promoter.
Blocking AP-1 binding with dominant-negative c-jun led
to decreased basal expression and significantly blocked
the TBH-induced increase in promoter activity and
mRNA level of all three genes. In conclusion, AP-1 is
required for basal expression of GCL and GS; while NF1
serves as a repressor of GS, increased AP-1 transactiva-
tion is the predominant mechanism for coordinate in-
duction of GCL and GS expression by TBH.
GSH is the main non-protein thiol in mammalian cells that
participates in many critical cellular functions including anti-
oxidant defense and cell growth (1–3). The synthesis of GSH
from its constituent amino acids involves two ATP-requiring
enzymatic steps: the formation of -glutamylcysteine from glu-
tamate and cysteine, and formation of GSH from -glutamyl-
cysteine and glycine. The first step of GSH biosynthesis is
generally regarded as rate-limiting and catalyzed by gluta-
mate-cysteine ligase (GCL,1 also known as -glutamylcysteine
synthetase), whereas the second step is catalyzed by GSH
synthetase (GS) (1). The GCL enzyme is composed of a catalytic
(GCLC, Mr 73,000) and a modifier (GCLM, Mr 30,000) sub-
unit that are encoded by different genes and dissociate under
reducing conditions (4–6). The catalytic subunit exhibits all of
the catalytic activity of the isolated enzyme as well as feedback
inhibition by GSH (6). The modifier subunit is enzymatically
inactive but plays an important regulatory function by lower-
ing the Km values of GCL for glutamate and raising the Ki
value for GSH (5, 7). Because GCL is a major determinant of
the overall GSH synthesis capacity, regulation of GCL subunits
has been a topic of extensive research (1). Changes in GCL
activity can result from regulation at multiple levels affecting
only the catalytic or modifier subunit or both. Both human and
rat GCL promoters have been cloned (8–12). Antioxidant re-
sponse element (ARE, also known as electrophile-response el-
ement) and activator protein 1 (AP-1) are two cis-acting ele-
ments present in the promoter of both human GCL subunits
that have been implicated in their transcriptional regulation by
oxidants and -naphthoflavone (1, 8–10). In contrast, the
cloned 5-flanking regions of the rat GCL subunits do not
contain AREs but contain both AP-1 and nuclear factor B
(NFB) consensus binding sites (11, 12).
Although much is known about GCL regulation, little atten-
tion has been paid to GS. The gene encoding GS was cloned in
1995 (13), but its transcriptional regulation is poorly under-
stood. By using treatments that are known to influence the
expression of hepatic GCL subunits, we found that treatments
such as tert-butylhydroquinone (TBH), diethyl maleate, and
buthionine sulfoximine, which increase the expression of both
subunits in rat hepatocytes, also increased the expression of GS
(14). Increased GS expression further enhanced the capacity of
the cell to synthesize GSH. In order to better understand tran-
scriptional regulation of GS, we have cloned and characterized
a 2.2-kb 5-flanking region of the rat GS. In this report, we also
examined the mechanism of coordinate induction of rat GCL
subunits and GS by TBH.
EXPERIMENTAL PROCEDURES
Materials—Cell culture media and fetal bovine serum were obtained
from Invitrogen. The Luciferase Assay System and the -Galactosidase
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Enzyme Assay System were obtained from Promega (Madison, WI).
All restriction enzymes were obtained from either Promega or
Invitrogen. [32P]dCTP and [-32P]ATP (3000 Ci/mmol) were purchased
PerkinElmer Life Sciences. Total RNA isolation kit was obtained from
Invitrogen. All other reagents were of analytical grade and were ob-
tained from commercial sources.
Cloning of the 5-Flanking Region of the Rat GS Gene—An oligonu-
cleotide probe corresponding to 38 to 2 of the rat GS cDNA (13) was
used to screen the rat genomic library EMBL 3 (CLONTECH, Palo Alto,
CA). Ten positive plaques were selected; DNA was isolated and digested
with EcoRI. The insert fragment was subcloned into pGL-3 enhancer
vector (Promega) and sequenced in both directions using the automated
ABI Prism dRhodamine Terminator Cycle Sequencer performed by the
Sequencing Core Facility, Norris Cancer Center, Keck School of Medi-
cine, University of Southern California. The initial primers were uni-
versal primers for the pGL-3 enhancer vector, and all subsequent prim-
ers were nested primers designed using the available sequence
information and the MacVector software program. The nucleotide se-
quence was verified by multiple bi-directional sequencing reactions.
Sequences were aligned, and a consensus sequence was generated using
the ASSEMBLIGN software program. A 2.19-kb 5-flanking region of
the rat GS was cloned into the SmaI site of promoterless pGL-3 en-
hancer vector creating the recombinant plasmid 2187/2 GS-LUC.
Primer Extension Analysis—Primer extension analysis was done as
described (11). Two antisense oligonucleotide primers complementary
to 24 to 2 and 27 to 2 nucleotides relative to the translational
start site of the rat GS (13) were end-labeled with [-32P]ATP using T4
polynucleotide kinase. Two and a half g of poly(A) RNA from H4IIE
cells isolated as described (15) was annealed to 106 cpm of the primers
and extended with 4 units of Vent DNA polymerase (New England
Biolabs, Inc.). The primer extended products were analyzed on 7 M urea,
6% polyacrylamide gels.
Construction of 5-Deletion Constructs—The 2.19-kb fragment in the
sense orientation upstream of the luciferase coding sequence of the
pGL-3 enhancer vector (Promega) is the construct that contains
the longest 5-flanking sequence (2187 to 2) employed in the trans-
fection assay. To prepare 5-deletion constructs, this plasmid was sub-
jected to digestion with additional restriction enzymes to generate a
series of deletion mutants. The enhancer/reporter transgene 1808/2
GS-LUC was created by cloning an EcoRI fragment. 1164/2 GS-LUC
was created by using the Erase-a-Base System kit (Promega), which
uses an exonuclease III that digests only 5-overhangs or blunt-ended
sites. The resulting DNA fragment containing the luciferase expression
vector was blunt-ended by Klenow (Invitrogen) and self-ligated by T4
DNA ligase. 561/2 GS-LUC was created by cloning a KpnI fragment,
and 252/2 GS-LUC was created by cloning a StuI fragment.
Recombinant Plasmids and Adenoviral Vectors—Rat GCLC and
GCLM promoter-luciferase constructs were previously described (11,
12). Recombinant, replication-defective adenovirus expressing domi-
nant-negative c-jun, TAM67, was kindly provided by Dr. David Brenner
(16). TAM67 is a truncation mutant of c-jun that lacks the transacti-
vation domain, whereas the DNA binding domain remains intact, per-
mitting dimerization with other AP-1 family members and inhibiting
AP-1-mediated transcription (16).
Infection of H4IIE Cells with Adenovirus Encoding TAM67—Recom-
binant adenoviruses encoding TAM67 or empty vector were amplified in
293 cells. H4IIE cells grown according to instructions provided (Amer-
ican Type Culture Collection number CRL-1548) were infected with
unpurified recombinant adenovirus encoding for TAM67 or empty vec-
tor at multiplicity of 20 plaque-forming units/cell for 24 h. In prelimi-
nary experiments, this condition yielded maximum expression of
TAM67 as determined by Northern blot analysis (not shown). After 24 h
of infection, the viruses were removed and replaced with fresh medium
for transfection analysis as described below.
Analysis of Promoter Constructs in Cell Culture—Relative transcrip-
tional activity of the GS promoter fragments was studied using H4IIE
cells transiently transfected with GS promoter-luciferase constructs for
7 h using the Superfect Transfection Reagent (Qiagen, Valencia, CA) as
we described previously (11, 12). To study the effect of nuclear factor 1
(NF1) binding on GS promoter activity, the NF1 site at 1025 (NF1-1)
was mutated from ACCAGACCACCCATCTGCCAACTCTGT to ACCA-
GACCACCCATCTTAAAACTCTGT (NF1m1), and the NF1 site at
FIG. 1. Nucleotide sequence of the 5-flanking region of the rat
GS gene. Sequence is numbered relative to the translational start site.
The putative regulatory elements are indicated in boldface letters above
the underlined sequences.
FIG. 2. Determination of the transcriptional start site of the
rat GS gene by primer extension analysis. Two 32P-end-labeled
primers complementary to 24 to 2 (primer 1 or P1) and 27 to 2
(primer 2 or P2) of the rat GS cDNA were annealed to poly(A) RNA
from H4IIE cells or yeast tRNA (primer 2 was used) and extended with
Vent DNA polymerase as described under “Experimental Procedures.”
Size markers correspond to ØX174 digested with HinfI. Lane GA
represents a Maxam-Gilbert sequencing reaction in the same fragment.
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808 (NF1-2) was mutated from TACACACCCTGGCTTGGTGCCT-
CACCA to TACACACCCTGGCTTGGTTAATCACCA (NF1m2), where
the binding sites are underlined and the mutated sequence is shown in
bold. Mutation was performed by PCR and confirmed by restriction
enzyme digestion and sequencing. H4IIE cells were transfected with
1164/2 GS-LUC that contained wild type, NF1m1 (first NF1 site is
mutated) or NF1m1m2 (both NF1 sites are mutated), and the effect of
the mutation was assessed by measuring luciferase activity.
The effect of TBH on GS promoter activity was examined by meas-
uring luciferase activity driven by GS promoter luciferase gene con-
structs in transfected H4IIE cells treated with TBH (60 M) during the
last 4 h of the transfection. To study the effect of blocking AP-1 activity,
H4IIE cells infected previously with TAM67 or adenoviral vector alone
were transfected with GS promoter constructs and treated with TBH
(60 M for 4 h). The same types of studies were also carried out using rat
GCLC and GCLM promoter constructs.
Effect of TBH on the Expression of GCL Subunits and GS in H4IIE
Cells—H4IIE cells were treated with 0–120 M TBH for 4 h or 60 M for
0–12 h. In some experiments, cells had been infected with adenovirus
encoding dominant-negative c-jun or adenovirus vector alone prior to
TBH treatment. At the end of the TBH treatment, total RNA was
extracted, and Northern hybridization analysis was performed using
specific rat GCLC, GCLM, GS, c-jun, and -actin cDNA probes as
described (14). The c-jun cDNA probe corresponds to nucleotides 362–
882 of the published rat c-jun sequence (17) and was obtained by
reverse transcription and PCR using a one-step reverse transcriptase-
PCR kit (CLONTECH). Results of Northern blot analysis were normal-
ized to -actin.
DNase I Footprinting Analysis—32P-End-labeled fragments of the
5-flanking region of rat GS strongly induced by TBH treatment were
generated by digestion with restriction endonucleases. DNase I foot-
printing analysis was performed using double-stranded fragments cor-
responding to nucleotides 1207 to 997, 938 to 769, 768 to 561,
563 to 252, and 252 to 2 of the rat GS gene. These fragments
were cloned into the TA vector (Invitrogen). Singly end-labeled frag-
ments were generated with [-32P]ATP using T4 polynucleotide kinase,
and the DNase I footprinting procedure was performed as we described
previously (11).
EMSA and Supershift Assay—EMSAs for different regions of the rat
GS promoter were done as described previously (11, 12) using 5–15 g
of nuclear protein from H4IIE cells treated with TBH (60 M for 4 h) or
vehicle control (Me2SO). The probes used included putative AP-1-bind-
ing sites (11 nucleotides long) at 1098, 902, 896, 856, 844,
607, 343, 339, 326, 218, 192, and 91 (flanked by 5-CTTGA
and GCCGG-3 for each probe), Sp1-binding site at 689 (DNA frag-
ment corresponds to 694 to 674), NF1-binding sites at 1025 (NF1-
1), and 808 (NF1-2) that contain either wild type or mutated sequence
(NF1m1 and NF1m2) as described above.
Supershift analysis was performed with specific anti-c-jun, anti-Sp1,
and anti-NF1 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA)
as described previously (11). To assess the effect of dominant-negative
c-jun, cells were previously infected with TAM67 and subsequently
treated with TBH (60 M for 4 h) and processed for EMSA and super-
shift analysis.
Statistical Analysis—Data are given as mean  S.E. Statistical anal-
ysis was performed using ANOVA followed by Fisher’s test for multiple
comparisons. For changes in mRNA levels, ratios of GCL subunits and
GS to -actin densitometric values were compared by ANOVA. Signif-
icance was defined by p  0.05.
RESULTS
Cloning and Sequencing of the 5-Flanking Region of the Rat
GS—The sequence of the 2.19-kb product is shown in Fig. 1.
Analysis of the transcription factor binding site was done
using Transcription Factor Search (www.cbrc.jp/research/db/
TFSEARCH.html) and MatInspector version 2.2 (www.gsf.de/
cgi-bin/matsearch.pl). The 5-flanking region of the rat GS con-
tains numerous consensus binding sites for AP-1 and transcrip-
tion factor 11. It also contains several consensus binding sites
for CAAT enhancer-binding protein, myeloid zinc finger 1,
NF1, nuclear factor-erythroid 2 related factor 2, hepatocyte-
enriched nuclear factor-3b, Sp1, and one binding site for NFB
and heat shock transcription factor 2.
Transcriptional Start Site—Primer extension was used to
determine the transcriptional start site. Two antisense oligo-
nucleotide primers complementary to 24 to 2 (primer 1) and
27 to 2 (primer 2) nucleotides relative to the translational
start site of the rat GS (13) were annealed to poly(A) RNA
from H4IIE cells and extended toward the 5 end of the mRNA
by reverse transcription. Fig. 2 shows the primer extension
reaction yielded products of 53 and 49 nucleotides long using
primers 1 and 2, respectively. These products were not detected
FIG. 3. Transient transfection anal-
ysis of the rat GS promoter-luciferase
constructs in H4IIE cells. Progressive
5-deletions of the GS promoter extending
from 2187 to 2 bp were generated and
fused to the promoterless luciferase
pGL-3 enhancer vector as described un-
der “Experimental Procedures.” Number-
ing is defined relative to the translational
start site. In some experiments, cells were
previously infected with adenoviral vec-
tors encoding dominant-negative c-jun or
adenoviral vectors alone prior to transfec-
tion with GS promoter-luciferase con-
structs. Cells were then treated with ve-
hicle control (Me2SO) or TBH (60 M for
4 h) prior to cell harvest. Results repre-
sent mean  S.E. from three to six inde-
pendent experiments performed in tripli-
cate. Data are expressed as relative
luciferase activity to that of pGL-3 en-
hancer vector control, which is assigned a
value of 1.0. *, p  0.05 versus respective
control or adenoviral vector alone; †, p 
0.05 versus TBH  adenoviral vector
treated (ANOVA followed by Fisher’s
test).
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when the assay was carried out using tRNA (not shown). These
results are consistent with the transcriptional start site being
located 51 nucleotides upstream of the translational start site.
Functional Analysis of the 5-Flanking Region of Rat GS—To
delineate sequences that drive the expression of the rat GS, five
5-terminal nested deletion mutants ranging from 2187/2 to
252/2 were cloned into the promoterless luciferase reporter
gene vector pGL3 enhancer. The promoterless construct pGL3
enhancer served as the background control. Luciferase activity
was measured after transient transfection of H4IIE cells with
these constructs. Fig. 3 shows that the rat GS promoter was
able to drive efficiently luciferase expression in H4IIE cells.
The construct 561/2 produced maximal promoter activity
(61-fold increase over pGL-3) whereas the construct 1164/2
produced about 11% of maximal activity, indicating presence of
important elements between 561 and 51 and 1164 and
561 that positively or negatively regulated the promoter ac-
tivity, respectively. Inclusion of an additional 1 kb upstream
had no significant influence on the promoter activity.
Transcription Factor NF1 Mediates Repression of the Rat GS
Gene—We next investigated the mechanism of repression in
the region between 1164 and 561 of the GS promoter. Of the
consensus binding sites present in this region, NF1 is of inter-
est because it has been described to act as a transcriptional
repressor (18, 19). To examine the effect of the two NF1-binding
sites on the GS promoter, we performed EMSA with supershift
analysis using double-stranded probes that span these two
NF1 sites that contain either wild type or mutated sequence,
and we measured luciferase activity driven by the GS promoter
construct 1164/2-LUC that contains wild type, NF1m1 (first
NF1 site is mutated), or NF1m1m2 (both NF1 sites are mutat-
ed). Fig. 4 shows that NF1 binds to both of these sites, but
especially to site 2, and mutation of the first NF1 site led to a
5-fold increase in luciferase activity, whereas mutation of both
NF1 sites led to a 16-fold increase in luciferase activity.
Effect of TBH on GCL, GS, and c-jun Expression in H4IIE
Cells—We had shown previously that TBH induced the expres-
sion of both GCL subunits and GS in rat hepatocytes (14, 20).
By having cloned the promoter region of all three genes, we are
poised to investigate the molecular mechanism(s) responsible
for the coordinate induction in gene expression. We first estab-
lished the dose- and time-dependent effect of TBH on the ex-
pression of GSH synthetic enzymes in H4IIE cells (Fig. 5, A and
B). Maximum induction was observed with 4 h of treatment of
60 M TBH, which was used as the treatment protocol for all
subsequent studies involving TBH. TBH also induced a tran-
sient increase in the mRNA level of c-jun (Fig. 5C).
Effect of TBH on GCL and GS Promoter Activity in H4IIE
Cells—We next examined the effect of TBH treatment on the
promoter activity of GCL subunits and GS. Fig. 3 shows that
TBH treatment induced markedly the reporter activity driven
by the GS promoter, particularly the promoter construct 1164
to 2, where TBH led to a 35-fold increase in activity. Table I
summarizes the effect of TBH treatment on the promoter ac-
tivity of the two GCL subunits. Similar to the effect on GS
promoter, TBH also induced markedly the activity of both GCL
subunit promoters. Maximum induction was seen with the
GCLC construct 707/2-LUC (about 10-fold over control) and
GCLM construct 441/1-LUC (about 13-fold over control).
DNase I Footprinting Analysis of Rat GS 5-Flanking Re-
gion—To delineate the cis-acting elements that may be in-
volved in mediating the effect of TBH on the GS promoter,
DNase I footprinting analysis of the 1.2-kb 5-flanking region of
the GS gene was carried out. Fig. 6 shows footprinting results
using probes that span the region 1207 to 2. Nuclear protein-
dependent DNase I-protected areas are present in regions
1065 to 1036, 901 to 830, 707 to 679, 354 to 314,
and 104 to 68. Except for the region 707 to 679, the
other regions all contain multiple AP-1-binding sites.
EMSA and Supershift Analysis—Because AP-1 is known to
be induced by TBH (21) and there are 12 AP-1-binding sites in
the 1.08-kb 5-flanking region of the GS gene, we next exam-
ined which of these may be affected by TBH treatment. Fig. 7
shows increased AP-1 binding to six of the potential AP-1 sites
(1058, 896, 844, 343, 326, and 91) in response to
TBH treatment. This was confirmed by supershift analysis
using anti-c-jun antibodies (Fig. 7). However, the other six
potential AP-1-binding sites (902, 856, 607, 339, 218,
and 192) exhibited no change in AP-1 binding in response to
TBH treatment (data not shown).
FIG. 4. Role of NF1 binding on GS promoter activity. NF1 bind-
ing to two sites (NF1-1 at 1025 and NF1-2 at 808) of the GS
promoter was assessed by EMSA and supershift (A). Nuclear protein
extracts (5–15 g) were obtained from H4IIE cells, and EMSA with
supershift was done using probes that span the two NF1 sites that
contain either wild type or mutated sequence (NF1m1 and NF1m2) as
described under “Experimental Procedures.” The arrowheads to the
right point to specific complexes that were competitively blocked when
15 g of nuclear protein was incubated with radiolabeled probes in the
presence of 50 unlabeled specific probes (lower arrowhead) and su-
pershifted in the presence of specific antibodies to NF1 (top arrowhead).
Effect of mutating the NF1-binding sites on GS promoter activity was
assessed by measuring luciferase activity in H4IIE cells transfected
with 1164/2 GS-LUC that contained wild type, NF1m1 (first NF1
site is mutated), or NF1m1m2 (both NF1 sites are mutated) (B). Results
represent mean  S.E. from six independent experiments performed in
triplicate. Data are expressed as relative luciferase activity to that of
pGL-3 enhancer vector control, which is assigned a value of 1.0. *, p 
0.05 versus pGL-3; **, p  0.05 versus pGL-3 and 1164/2-LUC; †, p 
0.05 versus pGL-3, 1164/2-LUC, and 1164/2-NF1m1-LUC
(ANOVA followed by Fisher’s test).
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Although the region 707 to 679 of the GS promoter does
not contain AP-1 element, it contains an Sp1 element (689 to
680). We next investigated whether TBH treatment also in-
duced Sp1 binding. Fig. 8 shows that there is also a striking
increase in Sp1 binding to this Sp1 site in response to TBH.
Role of AP-1 in Basal and TBH-induced Increase in the
Expression of GSH Synthetic Enzymes—To evaluate the impor-
tance of AP-1 in both the basal expression and in the TBH-
mediated increase in expression of GSH synthetic enzymes,
H4IIE cells were infected with dominant-negative c-jun, and
the effect of blocking AP-1 activity on TBH-mediated changes
was examined. Fig. 9 shows that the basal expression of both
GCL subunits and GS fell when AP-1 activity was blocked (both
GCLM and GS decreased by more than 50%; GCLC fell by
30%). The TBH-mediated increase in the mRNA level of all
three genes was also significantly blocked.
Dominant-negative c-jun also blocked significantly the TBH-
mediated increase in AP-1 binding to the GS promoter (Fig. 7),
and reporter activity driven by GCLC, GCLM, and GS promot-
ers (Fig. 3 and Table I). Note that the basal promoter activity
was reduced by 40–50% in all of the promoter constructs (Fig.
3 and Table I).
In addition to blocking AP-1 binding to the GS promoter,
dominant-negative c-jun also reduced significantly Sp1 binding
to the Sp1 site at 689 to 680 of the GS promoter under basal
conditions and in response to TBH treatment (Fig. 8). Note that
c-jun does not bind directly to the Sp1 site as supershift oc-
curred with anti-Sp1 antibodies but not anti-c-jun antibodies
(Fig. 8).
DISCUSSION
GSH is the most abundant non-protein thiol that is impor-
tant in numerous cellular processes including antioxidant de-
fense, storage of cysteine, and maintenance of the redox state
(1). One of the major determinants of the synthesis of GSH is
the activity of GCL. Because of its importance, regulation of
GCL has been a topic of extensive research (1). In contrast,
little attention has been paid to GS. GS deficiency in humans
can result in dramatic metabolic consequences because the
accumulated -glutamylcysteine is converted to 5-oxoproline
which can cause severe metabolic acidosis, hemolytic anemia,
and central nervous system damage (13, 22). Mutation inacti-
vation of GS has been described (22). Recently two reports have
shown a selective fall in GS activity which resulted in lowered
GSH level (23, 24). If GCL is rate-limiting, how can a change in
GS activity influence the steady state GSH level? Although the
specific activity of GS is normally 2–4 times that of GCL
activity in normal liver (25), this may not be the case in other
tissues. In fact, in normal human skeletal muscle, the specific
activity of GS was only 36% higher than that of GCL (24).
FIG. 5. Effect of TBH on GCL sub-
units and GS and c-jun expression in
H4IIE cells. RNA (25 g/lane) samples
from H4IIE cells treated with 60 M TBH
for 0–12 h (A), 0–120 M for 4 h (B), or 60
M for 0–4 h (C) were analyzed by North-
ern blot analysis with a 32P-labeled GCLC
cDNA or c-jun probe as described under
“Experimental Procedures.” The same
membrane was then sequentially rehy-
bridized with 32P-labeled GCLM, GS, and
-actin cDNA probes (A and B) or only
-actin cDNA probe (C). Representative
Northern blots are shown.
TABLE I
Effects of TBH and dominant-negative c-Jun on GCLC and GCLM promoter activities
Results represent mean  S.E. from 3 to 6 separate experiments expressed as fold of pGL-3 enhancer vector. H4IIE cells were transfected with
GCLC or GCLM promoter-luciferase constructs and treated with 60 M TBH for the last 4 h of the transfection as described under “Experimental
Procedures.” To examine the effect of dominant-negative c-Jun (DN c-Jun), H4IIE cells were previously infected with adenoviral vectors encoding
DN c-Jun or adenoviral vectors alone prior to transfection with 707/2 GCLC-LUC or 441/1 GCLM-LUC constructs. Cells were then treated
with vehicle control (Me2SO) or TBH (60 M) for 4 h). Adenoviral vector alone and Me2SO had no effect on the luciferase activity.
Promoter constructs Control TBH DN c-Jun DN c-Jun  TBH
GCLC
pGL-3-LUC 1.0  0 0.9  0.03
113/2-LUC 1.7  0.1 1.9  0.1
597/2-LUC 87.4  0.9 387.6  26.0a
707/2-LUC 48.7  6.3 474.8  10.5a 24.1  4.5a 116.7  11.6b
1110/2-LUC 75.2  7.0 427.6  36.2a
1760/2-LUC 62.1  7.5 418.0  21.6a
GCLM
pGL-3-LUC 1.0  0 1.2  0.1
154/1-LUC 2.6  0.2 40.4  6.7a
441/1-LUC 18.6  3.2 247.1  26.5a 8.6  0.8a 44.8  2.9b
649/1-LUC 86.0  9.7 231.9  31.9a
850/1-LUC 57.2  3.6 148.5  15.4a
1251/1-LUC 8.6  1.9 20.6  4.2a
1850/1-LUC 8.7  2.2 18.9  4.9a
a p  0.05 versus respective controls.
b p  0.05 versus TBH treatment by ANOVA.
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Surgical trauma selectively reduced GS activity, which became
rate-limiting (24). Collectively these results suggest regulation
of GS has been overlooked and may be just as important in
determining the overall GSH synthetic capacity as GCL under
certain conditions and in non-hepatic tissues.
By using treatments that are known to influence the hepatic
GCL subunit expression, we found treatments that increase
the expression of both GCL subunits also increased the expres-
FIG. 6. Effect of TBH treatment on
DNase I footprinting analysis of
the 1207 to 997, 938 to 769, 768
to 561, 563 to 252, and 252 to 2
regions of the rat GS promoter. DNA
fragment containing 1207 to 997 (low-
er strand), 938 to 769 (upper strand),
768 to 561 (lower strand), 563
to 252 (upper strand), and 252 to 2
(upper strand) regions of the rat GS pro-
moter were end-labeled and digested with
DNase I in the absence (0) or presence of
10 g of nuclear protein extracts from
H4IIE cells treated with vehicle control
(Con) (Me2SO) or TBH (60 M for 4 h).
Positions of the protected regions are in-
dicated at the right of the figures. Lanes
GA represent a Maxam-Gilbert se-
quencing reaction in the same fragments.
FIG. 7. Effect of TBH and dominant-negative c-jun (AP1()) on electrophoretic mobility shift and supershift assays for different
AP-1-binding sites of the rat GS promoter. Nuclear protein extracts (5–15 g) were obtained from H4IIE cells treated with vehicle control
(CON) (Me2SO) or TBH (60 M for 4 h), and EMSA with supershift was done as described under “Experimental Procedures” using probes that span
different AP-1-binding sites of the rat GS promoter (A). B, H4IIE cells were infected with adenoviral vectors encoding dominant-negative c-jun
(AP1()) or adenoviral vector alone and subsequently treated with TBH. Note that TBH treatment led to increased AP-1 binding that was inhibited
significantly if cells were treated previously with dominant-negative c-jun. Similar findings were obtained with probes 896 to 886, 844 to
834, and 343 to 333 (not shown). The arrows to the right point to specific complexes that were competitively blocked when 15 g of nuclear
protein from TBH-treated cells was incubated with radiolabeled probes in the presence of 50 unlabeled specific probes (lower arrow) and
supershifted in the presence of specific antibodies to c-jun (top arrow).
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sion of GS (14). This coordinated induction in GS and GCL led
to higher GSH synthetic capacity than induction in GCL alone
(14). To better understand GS transcriptional regulation and
how coordinated regulation of GSH synthetic enzymes occur,
we have cloned and characterized the rat GS promoter and
elucidated the molecular mechanism of TBH-induced coordi-
nated increase in the expression of GSH synthetic enzymes.
The sequence of 5-flanking region of the rat GS contains
numerous AP-1 and transcription factor 11-binding sites but no
ARE site. This is similar to the rat GCL subunit promoters,
which also lack ARE elements (11, 12). Primer extension anal-
ysis revealed a single transcriptional start site located 51 nu-
cleotides upstream of the translational start site. Transfection
studies showed that the 5-flanking sequence of the rat GS gene
contains a functional promoter that was able to drive luciferase
expression in H4IIE cells efficiently. Maximal promoter activ-
ity was obtained with the GS promoter construct 561/2-
LUC, denoting the presence of enhancer element(s) in this
region. In contrast, the presence of repressor element(s) is
suggested between 1164 and 561 as the promoter activity
fell almost 9-fold. By using EMSA, supershift, and site-directed
mutagenesis analyses, we found NF1 to be a strong repressor of
the rat GS promoter. NF1 binds to both sites (1025 and
808), and when binding is prevented by mutagenesis, the
resulting promoter activity surpassed the maximal activity
obtained with the 561/2-LUC construct, suggesting that
many of the enhancer elements (i.e. the AP-1 sites) in the
region between 1164 and 561 were suppressed.
By having cloned the promoter region of both GCL subunits
(11, 12) and GS in the rat and having shown that TBH induces
comparably the expression of all three genes in rat hepatocytes
(14), we next examined the molecular mechanism(s) of this
coordinate induction. TBH has been shown by others to induce
the nuclear binding activity of AP-1, NFB, and ARE (21, 26).
However, it has also been shown to induce the human GCLM
promoter activity independent of ARE or AP-1 (27). Similar to
rat hepatocytes, TBH exerted a comparable increase in the
mRNA levels of both GCL subunits and GS in the rat hepatoma
cell line H4IIE in a dose- and time-dependent manner. TBH
also induced strongly the reporter activity driven by all three
promoter-luciferase constructs, although with varying magni-
tude depending on the length of the construct. DNase I foot-
printing analysis was next used to elucidate possible cis-acting
elements involved in mediating the effect of TBH. After TBH
treatment, there was a dramatic increase in protein binding to
several regions of the GS promoter, and all except one is rich in
AP-1 sites. EMSA with supershift was then used to see which
of the 12 potential AP-1 sites present in the 1.1-kb 5-flanking
region of the GS gene exhibited increased binding after TBH
treatment. Consistent with results obtained with DNase I foot-
printing, increased AP-1 binding activity was confirmed with
EMSA and supershift analysis to putative AP-1-binding sites
at 1058, 896, 844, 343, 326, and 91. Similarly, no
FIG. 8. Effect of TBH and dominant-
negative c-jun (AP1()) on electro-
phoretic mobility shift and super-
shift assays for Sp1-binding site at
689 of the rat GS promoter. H4IIE
cells were infected with adenoviral vec-
tors encoding dominant-negative c-jun or
adenoviral vectors alone and subse-
quently treated with TBH (60 M for 4 h)
or vehicle control (CON). Nuclear protein
extracts (15 g) were obtained after vari-
ous treatments, and EMSA was done as
described under “Experimental Proce-
dures” using probe 694 to 674 of the
GS promoter. The arrows are pointing to
the TBH-induced increase in Sp1 binding
(lower arrow) which is confirmed by su-
pershift analysis using specific anti-Sp1
antibodies (upper arrow). No supershift
occurred in the presence of anti-c-Jun an-
tibodies (Ab).
FIG. 9. Effect of TBH and dominant-negative c-jun (AP1()) on
steady state mRNA levels of GCL subunits and GS. H4IIE cells
were infected with adenoviral vectors encoding dominant-negative c-
jun or adenoviral (Ad) vectors alone and subsequently treated with
TBH (60 M for 4 h) or vehicle control (Con). Northern blot analysis was
carried out with RNA (25 g/lane) samples after various treatments
using a 32P-labeled GCLC cDNA probe as described under “Experimen-
tal Procedures.” The same membrane was then sequentially rehybrid-
ized with 32P-labeled GCLM, GS, and -actin cDNA probes. Represent-
ative Northern blots are shown.
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increase in protein or AP-1 binding activity was detected to
putative AP-1-binding sites at 607, 218 or 192 with
DNase I footprinting or EMSA analysis, respectively. Although
putative AP-1-binding sites at 902, 856, and 339 are in
the regions found to have increased protein binding after TBH
treatment on DNase I footprinting analysis, no change in AP-1
binding activity was detected with EMSA. TBH treatment also
led to increased Sp1 binding to the Sp1 site at 689 to 680,
which is in the region detected to have increased protein bind-
ing on DNase I footprinting analysis but devoid of AP-1 site.
To confirm that AP-1 binding led to transactivation of the
gene, cells were infected with dominant-negative c-jun prior to
TBH treatment. Blocking AP-1 activity led to a fall in the basal
mRNA level of all three genes and their constitutive promoter
activities. This finding is similar to what has been reported also
for the human GCL subunit promoters and GCLC mRNA level,
where AP-1 activity is required for constitutive activity and
basal expression (27–29). However, blocking AP-1 activity also
blocked significantly the TBH-mediated increase in the pro-
moter activity of the rat GCL subunits and GS as well as the
mRNA levels of all three genes. The inhibition was not com-
plete, however, which may reflect that fact that increased AP-1
binding was not completely abolished (see Fig. 7). Of interest is
that blocking AP-1 activity also blocked the increase in Sp1
binding (Fig. 8). Recently direct physical interaction between
c-jun and Sp1 has been demonstrated, and c-jun was able to
synergize the transactivation of Sp1 without actually binding
to the DNA itself (30, 31). Consistent with this, we also did not
detect c-jun binding to the Sp1 site (Fig. 8). Our data suggest
that dominant-negative c-jun interacted with Sp1 and pre-
vented its binding to the GS promoter. This can explain the
decrease in Sp1 binding activity under basal conditions as well
as in response to TBH treatment (Fig. 8). It is likely that
functional cooperation between c-jun and Sp1 also contributes
to the TBH-mediated induction of GS. Finally, our data do not
preclude other AP-1-independent mechanism(s) in contributing
to the TBH-induced up-regulation of the GSH synthetic
enzymes.
In summary, we have cloned and analyzed the 5-flanking
region of the rat GS gene. The rat GS promoter contains both
positive and negative regulatory regions. NF1 is an important
repressor of the GS promoter. By using the cloned rat GCL and
GS promoters, we have identified AP-1 activity as essential for
their constitutive expression and for the up-regulation of all
three genes in response to TBH.
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